Galapagos and the National Cancer Institute sign compound management agreement
Galapagos NV announced that the Compound Focus subsidiary of its BioFocus service division has signed an agreement with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH). Under the terms of the agreement, BioFocus will provide compound management services to NCI for a base period of three years for a total of up to $5 million (€3.7 M), with two one-year extension options.
BioFocus runs a compound management facility for a number of industrial and U.S. government customers out of its Compound Focus, Inc. subsidiary in South San Francisco. Under the agreement, Compound Focus will establish a Small Molecule Repository for the NCI Chemical Biology Consortium (CBC). This repository will form part of the CBC's drug discovery and development platform for new oncology therapeutics being researched by a consortium of primarily academic institutions. The base three year contract is funded by American Recovery and Reinvestment Act (ARRA) funds.
Other news from the department business & finance
